Physician profile
Shailesh Vora
NPI 1902878473
$5,845.19
in general payments reported to CMS, 2019-2025
51 companies · $116 in 2025
The $116 reported for 2025 was less than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $14.00 · 2020: $469 · 2021: $1,959 · 2022: $2,497 · 2023: $790 · 2025: $116.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $906.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $905.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $523.68 | 2021-2023 | Ubrelvy, Vraylar, Qulipta |
| Biogen, INC. | $380.06 | 2021-2023 | Vumerity, Tysabri |
| Lilly USA, LLC | $316.24 | 2020-2023 | Reyvow, Emgality |
| Sunovion Pharmaceuticals INC. | $281.61 | 2020-2022 | |
| Genzyme Corporation | $266.94 | 2020-2023 | |
| Upsher-Smith Laboratories LLC | $256.92 | 2020-2023 | |
| Ucb, INC. | $255.44 | 2020-2023 | Nayzilam |
| Merz Pharmaceuticals, LLC | $247.27 | 2021-2022 | |
| Amgen INC. | $244.97 | 2021-2022 | |
| Kyowa Kirin, INC. | $223.49 | 2020-2023 | Nourianz |
| Horizon Therapeutics Plc | $175.86 | 2021-2023 | Uplizna |
| Supernus Pharmaceuticals, INC. | $175.57 | 2021-2025 | Qelbree |
| Sk Life Science, INC. | $152.51 | 2021-2022 | |
| Eisai INC. | $147.22 | 2020-2022 | |
| Harmony Biosciences LLC | $144.10 | 2021-2023 | Wakix |
Show all 51 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shailesh Vora listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.